secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2026-08-03T11:04:02+00:00
Accession:  0001711279-26-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q2 2026 revenue $119.2M (+24% YoY); net income $54.8M; cash $1.1B
--------------------------------------------------------------------------------

- Q2 2026 VYJUVEK global revenue $119.2M, up 24% YoY; gross margin 95%.
- Net income $54.8M ($1.85 basic EPS) vs $38.3M ($1.33) in Q2 2025.
- Cash and investments $1.1B; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.
- KB803 (ophthalmology) IOLITE study fully enrolled; top-line data expected 4Q 2026.
- KB407 (CF) interim results expected before year end; FDA alignment on registrational study design expected 4Q 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/0001711279-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/krys-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001711279-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer